Loading organizations...
§ Private Profile · London, United Kingdom
Health technology company providing personalized nutritional supplements based on AI-driven blood test analysis for health-conscious individuals.
Bioniq is a London, United Kingdom-based health technology company that develops personalized nutritional supplements based on individual blood test data and artificial intelligence algorithms. Operating through a direct-to-consumer subscription model, the enterprise analyzes user biomarkers to formulate custom daily micronutrient blends delivered as specialized granules rather than traditional pills. The platform utilizes a proprietary database containing over six million biochemical data points to optimize these formulas, and the business ships its products to consumers across more than 60 countries, with the United States accounting for over half of its customer base. In July 2024, the organization secured a $15 million Series B funding round led by investors Principal Investments and HV Capital, while also serving high-profile customers such as athlete Cristiano Ronaldo. Bioniq was founded in 2019 by Vadim Fedotov and Dr. Konstantin Karuzin.
Bioniq has raised $31.2M across 3 funding rounds.
Bioniq has raised $31.2M in total across 3 funding rounds.
Bioniq has raised $31.2M across 3 funding rounds. Most recently, it raised $1.2M Other Equity in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 18, 2025 | $1.2M Venture Round | — | — | Announced |
| Jul 1, 2024 | $15M Series B | HV Capital, Unbound | Norrsken VC, Picus Capital | Announced |
| Feb 9, 2022 | $15M Venture Round | — | — | Announced |
Bioniq is a UK-based health tech company launched in 2019 that builds AI-driven personalized supplements using blood test data and a proprietary biochemical database.[1][2][4] It serves individuals seeking optimized health—such as athletes, professionals, and wellness enthusiasts—by analyzing biomarkers like height, weight, age, lifestyle, and health goals to create tailor-made nutrient formulas addressing micronutrient deficiencies.[1][2][4] The core problem it solves is the inefficiency of one-size-fits-all supplements, delivering precise, evolving dosages via patented gradual-release granules for goals like better sleep, focus, and muscle mass.[1][4] With over 100,000 users across five continents, a $75M valuation post-$15M Series B in 2025, and high-profile backing from Cristiano Ronaldo, Bioniq shows strong growth through global expansion, lab integrations, and U.S./Middle East scaling.[1][4]
Bioniq was founded in 2019 in London, UK, by Vadim Fedotov, a former professional basketball player turned CEO (previously at GRPN), who experienced unexplained fatigue despite peak physical condition.[2] Doctors dismissed his symptoms, prompting Fedotov to explore Switzerland's personalized micronutrient approach, which resolved his issues and inspired the company.[2] He built it around a massive proprietary database of blood test data—now over 6 million data points from global customers—paired with a patent-pending AI algorithm.[1][4] Co-founder James Hardy, CFO with 20 years in retail, fintech, and eCommerce as a Chartered Accountant, handles finances, investor relations, market expansion, and fundraising.[2] Early traction came from partnerships with institutions like Lanserhof and King's College Hospital, acquisitions like VAHA.com and Loewi, and serving 100,000+ users.[1][2]
Bioniq rides the personalized nutrition and AI-health trend, fueled by rising demand for precision wellness amid biomarker testing accessibility and consumer skepticism of mass-market vitamins.[1][4] Timing aligns with post-pandemic health optimization booms, longevity tech advances, and AI's role in biotech—its database and algorithm set industry standards for data-driven supplementation.[1] Market forces like global wellness spending (projected trillions) and regulatory nods (SwissMedic, FDA) favor it, while partnerships with elite institutions amplify credibility.[2][4] Bioniq influences the ecosystem by normalizing blood-based personalization, inspiring competitors, and expanding via acquisitions/investors, pushing "one-size-fits-all" toward obsolescence.[1][2]
Bioniq's $15M Series B at $75M valuation positions it for aggressive growth: U.S./Middle East expansion, global lab networks, HR scaling, and institutional platforms will accelerate user acquisition beyond 100,000.[1] Trends like AI-biomarker integration, wearable health data, and elite athlete adoption (e.g., Ronaldo) will shape its path, potentially dominating personalized supps as databases grow. Its influence may evolve into a full health ecosystem—merging supps with diagnostics/apps—cementing it as the leader in making advanced nutrition accessible, just as Fedotov's personal quest sparked a global standard.[1][2][4]
Bioniq has raised $31.2M in total across 3 funding rounds.
Bioniq's investors include HV Capital, Unbound, Norrsken VC, Picus Capital.